Received Oct 16, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | UNK | — | IM |
severe case of late-onset eczema; This spontaneous case was reported by a consumer and describes the occurrence of ECZEMA (severe case of late-onset eczema) in an 83-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis. No Medical History information was reported. In 2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular use) 1 dosage form. In 2021, the patient experienced ECZEMA (severe case of late-onset eczema). At the time of the report, ECZEMA (severe case of late-onset eczema) had not resolved. No concomitant and treatment medication were provided. Patient experienced late-onset eczema shortly after first Moderna booster in 2021. The condition persists but was controlled with medication. Although each time patient got booster and had an eczema outbreak for about a month. Hence patient asked guidance on receiving new vaccine given tolerability of eczema versus risk of COVID. This case was linked to US-MODERNATX, INC.-MOD-2025-790142 (E2B Linked Report).; Sender's Comments: US-MODERNATX, INC.-MOD-2025-790142:Booster dose